Valvular heart disease
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. From January 1st, 2011 to December 31st, 2012, the patients who need heart valve replacement surgery and postoperative anticoagulation therapy by oral administration of warfarin and accept INR as the index to assess the safety and efficacy of anticoagulation therapy are included; 2. The patients without the history of hemorrhage diseases; 3. The patients with normal, at least near to normal hepatic and renal function. / The patients without the severe hepatic and renal dysfunction; 4. During the period of postoperative anticoagulation, the participants are forbidden for non-steroid anti-inflammation drugs and other drugs which could affect the body's coagulation function except for the participants who have heart valve replacement surgery and coronary artery bypass graft surgery simultaneously or in turn and also need anti-platelet drugs; 5. The patients and their guardians agree to participate in the research programs and sign the informed consent; 6. The patients with good compliance and can be contacted easily in order to complete the follow-up.
Exclusion criteria
Exclusion criteria: 1. The participants who cannot follow the doctor's order and take warfarin regularly. 2. The data of the follow-up is incomplete. The frequency for monitoring INR: In the first month after surgery, once a week; In the second and third months after surgery, once two week; In the fourth to sixth months after surgery, once a month; After postoperative half year, if the effect of anticoagulation therapy is stable, the frequency of monitoring INR can be controlled every three months. But in some regions of lack of medical facilities for monitoring INR, the frequency can be prolonged to every half year.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| International standard ratio (INR); | — |
Countries
China